Bank of Montreal Can acquired a new position in shares of Bioventus Inc. (NYSE:BVS - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 133,641 shares of the company's stock, valued at approximately $774,000. Bank of Montreal Can owned 0.17% of Bioventus at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in BVS. Quadrature Capital Ltd acquired a new stake in shares of Bioventus in the 4th quarter valued at about $85,000. GSG Advisors LLC grew its holdings in shares of Bioventus by 55.8% in the 1st quarter. GSG Advisors LLC now owns 26,511 shares of the company's stock valued at $133,000 after acquiring an additional 9,500 shares in the last quarter. LSV Asset Management bought a new position in shares of Bioventus in the 1st quarter valued at about $1,170,000. SG Americas Securities LLC bought a new position in shares of Bioventus in the 1st quarter valued at about $66,000. Finally, Acadian Asset Management LLC bought a new position in Bioventus during the first quarter worth about $28,000. Institutional investors and hedge funds own 62.94% of the company's stock.
Bioventus Stock Performance
NYSE BVS traded up $0.40 during trading on Tuesday, reaching $11.59. 417,705 shares of the company's stock were exchanged, compared to its average volume of 391,173. The business has a 50 day moving average price of $9.74 and a 200-day moving average price of $7.16. The stock has a market capitalization of $917.53 million, a P/E ratio of -33.23 and a beta of 0.90. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.33 and a quick ratio of 0.96. Bioventus Inc. has a fifty-two week low of $2.85 and a fifty-two week high of $12.41.
Bioventus (NYSE:BVS - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.07 by $0.12. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. The company had revenue of $151.22 million for the quarter, compared to the consensus estimate of $137.70 million. During the same quarter in the prior year, the business earned $0.14 earnings per share. Sell-side analysts forecast that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.
Insider Activity
In other news, Director John A. Bartholdson bought 25,500 shares of the firm's stock in a transaction dated Monday, August 19th. The shares were bought at an average price of $8.55 per share, with a total value of $218,025.00. Following the completion of the transaction, the director now owns 6,939,357 shares of the company's stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director John A. Bartholdson purchased 80,000 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the purchase, the director now owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John A. Bartholdson purchased 25,500 shares of the business's stock in a transaction that occurred on Monday, August 19th. The stock was bought at an average price of $8.55 per share, with a total value of $218,025.00. Following the completion of the purchase, the director now owns 6,939,357 shares of the company's stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 32.90% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on BVS shares. Craig Hallum boosted their price target on Bioventus from $12.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday, September 27th. Canaccord Genuity Group boosted their price target on Bioventus from $8.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, August 13th.
Check Out Our Latest Stock Report on Bioventus
Bioventus Profile
(
Free Report)
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
See Also
Before you consider Bioventus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.
While Bioventus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
